Show simple item record

dc.contributor.authorAtegyeka, Paul Mukama
dc.contributor.authorMuhoozi, Michael
dc.contributor.authorNaturinda, Racheal
dc.contributor.authorKageni, Peter
dc.contributor.authorNamugenyi, Carol
dc.contributor.authorKasolo, Amos
dc.contributor.authorKisaka, Stevens
dc.contributor.authorKiwanuka, Noah
dc.date.accessioned2023-04-06T10:01:51Z
dc.date.available2023-04-06T10:01:51Z
dc.date.issued2023
dc.identifier.citationAtegyeka, P. M., Muhoozi, M., Naturinda, R., Kageni, P., Namugenyi, C., Kasolo, A., ... & Kiwanuka, N. (2023). Prevalence and factors associated with reported adverse-events among patients on multi-drug-resistant tuberculosis treatment in two referral hospitals in Uganda. BMC Infectious Diseases, 23(1), 1-9.en_US
dc.identifier.urihttp://ir.must.ac.ug/xmlui/handle/123456789/2864
dc.description.abstractBackground Multi-drug-resistant tuberculosis (MDR-TB) treatment involves toxic drugs that cause adverse events (AEs), which are life-threatening and may lead to death if not well managed. In Uganda, the prevalence of MDR-TB is increasingly high, and about 95% of the patients are on treatment. However, little is known about the prevalence of AEs among patients on MDR-TB medicines. We therefore estimated the prevalence of reported adverse events (AEs) of MDR-TB drugs and factors associated with AEs in two health facilities in Uganda. Methods A retrospective cohort study of MDR-TB was conducted among patients enrolled at Mulago National Referral and Mbarara Regional Referral hospitals in Uganda. Medical records of MDR-TB patients enrolled between January 2015 and December 2020 were reviewed. Data on AEs, which were defined as irritative reactions to MDR-TB drugs, were extracted and analyzed. To describe reported AEs, descriptive statistics were computed. A modified Poisson regression analysis was used to determine factors associated with reported AEs. Results Overall, 369 (43.1%) of 856 patients had AEs, and 145 (17%) of 856 had more than one. Joint pain (244/369, or 66%), hearing loss (75/369, or 20%), and vomiting (58/369, or 16%) were the most frequently reported effects. Patients started on the 24-month regimen (adj. PR = 1.4, 95%; 1.07, 1.76) and individualized regimens (adj. PR = 1.5, 95%; 1.11, 1.93) were more likely to suffer from AEs. Lack of transport for clinical monitoring (adj. PR = 1.9, 95%; 1.21, 3.11); alcohol consumption (adj. PR = 1.2, 95%; 1.05, 1.43); and receipt of directly observed therapy from peripheral health facilities (adj. PR = 1.6, 95%; 1.10, 2.41) were significantly associated with experiencing AEs. However, patients who received food supplies (adj. PR = 0.61, 95%; 0.51, 0.71) were less likely to suffer from AEs. Conclusion The frequency of adverse events reported by MDR-TB patients is considerably high, with joint pain being the most common. Interventions such as the provision of food supplies, transportation, and consistent counseling on alcohol consumption to patients at initiation treatment facilities may contribute to a reduction in the rate of occurrence of AEs.en_US
dc.language.isoen_USen_US
dc.publisherBMC Infectious Diseasesen_US
dc.subjectMulti-drug resistanten_US
dc.subjectTuberculosisen_US
dc.subjectAdverse-eventsen_US
dc.titlePrevalence and factors associated with reported adverse-events among patients on multi-drug-resistant tuberculosis treatment in two referral hospitals in Ugandaen_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

  • Research Articles [456]
    These are different research articles about different Scholars

Show simple item record